Published October 28, 2026 · Compiled from the S-1/A filed on SEC EDGAR on 2026-10-26 and the Quintarthai IPO calendar. Quoted passages are the filing's own words.

Bambusa Therapeutics, Inc. (BBTX) IPO: what the S-1/A filing says

Bambusa Therapeutics, Inc. filed an S-1/A with the SEC on 2026-10-26 in connection with its US listing.

In the Quintarthai IPO calendar: status Upcoming, exchange NASDAQ, expected listing date Oct 30, 2026.

Use of proceeds (quoted from the filing)

• “Similarly, each increase or decrease of 1.0 million shares in the number of shares of common stock offered by us would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $14.9 million, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering…”
• “We intend to use the remaining proceeds to fund additional research and development activities of our two preclinical product candidates, BBT003 and BBT004, including advancing BBT003 into clinical development, as well as for capital expenditures, working capital, and general corporate purposes, including the additional costs of operating as a public company.”
• “Our expected use of the net proceeds from this offering represents our current intentions based upon our present plans and business conditions.”
• “As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above.”

Source: S-1/A on SEC EDGAR · IPO research page: BBTX.

Research and analysis only — not investment advice, not a recommendation to apply or avoid.